Read More Pharma Industry News Spark Therapeutics’ Luxturna gains EU approval as first gene therapy for inherited retinal disease In a significant breakthrough for treating inherited vision loss, Pennsylvania-based Spark Therapeutics has received European Commission (EC) approval… bypharmanewsdailyNovember 24, 2018
